InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Proactive Studio Podcast
May 16, 2023 at 15:56 PM EDT
Vivos Therapeutics (NASDAQ: VVOS) chairman and CEO Kirk Huntsman recently joined Natalie Stoberman from the Proactive Studio to discuss how the company’s POD device performed a highly effective rate in treating migraine headaches in a clinical study. During the interview, Huntsman said that the study showed 92% of patients reporting complete resolution of their symptoms, an unprecedented result for a non-pharmaceutical application in this field. He further expanded upon the device’s potential for other applications, such as treating upper airway resistance, TMD, bruxism, and various pain conditions, which require further research. Huntsman additionally discussed Vivos’ implementation of a broad set of initiatives aimed at improving operational efficiencies, reducing expenses and positioning Vivos to take advantage of current growth opportunities. The company projects it could hit the positive cashflow milestone at the beginning of 2024.
To view the full press release, visit https://ibn.fm/WPD3U
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild-to-moderate OSA. It has proven effective in over 33,000 patients treated worldwide by more than 1,750 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork